Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIM811 dose-finding study with standard of care in relapsed genotype 1 hepatitis C
NL-OMON33087Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2010
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NIM811 in chronic hepatitis C (CHC) (2 arms), sponsored by Novartis. Primary endpoints: HCV RNA measurements and Safety and tolerability. Started Apr 2010; status: active, not recruiting.
02
Drugs
NIM811
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NL-OMON33087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33087.